Patients with intermediate to high risk prostate cancer on biopsy are eligible for government‐funded PSMA PET/CT (primary staging) and restaging of patients with recurrent prostate cancer (PSA persistence/biochemical recurrence). Here, FOLH1 is linked to prostate cancer.